Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases.

Clarke PA, Ortiz-Ruiz MJ, TePoele R, Adeniji-Popoola O, Box G, Court W, Czasch S, El Bawab S, Esdar C, Ewan K, Gowan S, De Haven Brandon A, Hewitt P, Hobbs SM, Kaufmann W, Mallinger A, Raynaud F, Roe T, Rohdich F, Schiemann K, Simon S, Schneider R, Valenti M, Weigt S, Blagg J, Blaukat A, Dale TC, Eccles SA, Hecht S, Urbahns K, Workman P, Wienke D.

Elife. 2016 Dec 9;5. pii: e20722. doi: 10.7554/eLife.20722.

2.

In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis.

Eccles SA, Court W, Patterson L.

Methods Mol Biol. 2016;1430:121-47. doi: 10.1007/978-1-4939-3628-1_8.

PMID:
27172950
3.

PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion.

Dart AE, Box GM, Court W, Gale ME, Brown JP, Pinder SE, Eccles SA, Wells CM.

J Cell Biol. 2015 Nov 23;211(4):863-79. doi: 10.1083/jcb.201501072.

4.

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D, Schwarz D, Schneider K, Stubbs M, Ewan K, Fraser E, TePoele R, Court W, Box G, Valenti M, de Haven Brandon A, Gowan S, Rohdich F, Raynaud F, Schneider R, Poeschke O, Blaukat A, Workman P, Schiemann K, Eccles SA, Wienke D, Blagg J.

Nat Chem Biol. 2015 Dec;11(12):973-980. doi: 10.1038/nchembio.1952. Epub 2015 Oct 26.

5.

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.

Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT, Georgi K, Court W, Hobbs S, Box G, Ortiz-Ruiz MJ, Valenti M, De Haven Brandon A, TePoele R, Leuthner B, Workman P, Aherne W, Poeschke O, Dale T, Wienke D, Esdar C, Rohdich F, Raynaud F, Clarke PA, Eccles SA, Stieber F, Schiemann K, Blagg J.

J Med Chem. 2015 Feb 26;58(4):1717-35. doi: 10.1021/jm501436m. Epub 2015 Feb 13.

6.

A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells.

Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwie F, Cuda F, Court W, Fox KR, Townsend PA, Packham GK, Eccles SA, Tavassoli A.

J Am Chem Soc. 2013 Jul 17;135(28):10418-25. doi: 10.1021/ja402993u. Epub 2013 Jul 9.

7.

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles SA.

BMC Biol. 2012 Mar 22;10:29. doi: 10.1186/1741-7007-10-29.

8.

Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage.

Harvey AJ, Pennington CJ, Porter S, Burmi RS, Edwards DR, Court W, Eccles SA, Crompton MR.

Am J Pathol. 2009 Sep;175(3):1226-34. doi: 10.2353/ajpath.2009.080811. Epub 2009 Aug 6.

9.

The identification of novel PLC-gamma inhibitors using virtual high throughput screening.

Reynisson J, Court W, O'Neill C, Day J, Patterson L, McDonald E, Workman P, Katan M, Eccles SA.

Bioorg Med Chem. 2009 Apr 15;17(8):3169-76. doi: 10.1016/j.bmc.2009.02.049. Epub 2009 Mar 3.

PMID:
19303309
10.

In vitro assays for endothelial cell functions related to angiogenesis: proliferation, motility, tubular differentiation, and proteolysis.

Eccles SA, Court W, Patterson L, Sanderson S.

Methods Mol Biol. 2009;467:159-81. doi: 10.1007/978-1-59745-241-0_9.

PMID:
19301670
11.

Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck.

Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, Rhŷs-Evans P, O-charoenrat P, Eccles S.

Cancer Res. 2007 Aug 15;67(16):7907-16.

12.

The phosphoinositide-specific phospholipase C inhibitor U73122 (1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) spontaneously forms conjugates with common components of cell culture medium.

Wilsher NE, Court WJ, Ruddle R, Newbatt YM, Aherne W, Sheldrake PW, Jones NP, Katan M, Eccles SA, Raynaud FI.

Drug Metab Dispos. 2007 Jul;35(7):1017-22. Epub 2007 Apr 2.

PMID:
17403917
13.

Cell migration/invasion assays and their application in cancer drug discovery.

Eccles SA, Box C, Court W.

Biotechnol Annu Rev. 2005;11:391-421. Review.

PMID:
16216785
14.

A matter of standards: the quest for authentic, reproducible and reliable plant drugs.

Court WE.

Pharm Hist (Lond). 2002 Dec;32(4):50-8. No abstract available.

PMID:
12549505
15.

Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma.

Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, Martz K, Zeiger LS.

Cancer Invest. 2002;20(5-6):613-25.

PMID:
12197216
16.

ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR.

Anticancer Res. 2002 Jul-Aug;22(4):1993-9.

PMID:
12174876
17.

When the mirror doesn't reflect it at all.

Order SE, Court W.

J Clin Oncol. 2002 Feb 15;20(4):1144. No abstract available.

PMID:
11844839
18.

Ginseng: the history of an insignificant plant.

Court WE.

Pharm Hist (Lond). 2000 Sep;30(3):38-44. No abstract available.

PMID:
11624663
19.

The ancient doctrine of signatures or similitudes.

Court WE.

Pharm Hist (Lond). 1999 Sep;29(3):41-8. No abstract available.

PMID:
11623905
20.

The rauwolfia story: ancient herbal medicine - 20th century tranquilliser - 21st century reject?

Court WE.

Pharm Hist (Lond). 1998 Oct;28(3):43-8. No abstract available.

PMID:
11620520
21.

Intra-arterial cisplatin more effective than intravenous.

Order SE, Court WS.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1377. No abstract available.

PMID:
11503615
22.

Models of clinical infusional brachytherapy.

Order SE, Court WS.

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):279. No abstract available.

PMID:
11341241
23.
24.
25.

Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.

O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA.

Cancer Res. 2000 Feb 15;60(4):1121-8.

26.

Histologic morphometry confirms a prophylactic effect for hyperbaric oxygen in the prevention of delayed radiation enteropathy.

Feldmeier JJ, Davolt DA, Court WS, Onoda JM, Alecu R.

Undersea Hyperb Med. 1998 Summer;25(2):93-7.

PMID:
9670434
27.

Radiation therapy for endometrial cancer in patients treated for postoperative recurrence.

Hart KB, Han I, Shamsa F, Court WS, Chuba P, Deppe G, Malone J, Christensen C, Porter AT.

Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):7-11.

PMID:
9588911
28.

Hyperbaric Oxygen Therapy.

Feldmeier JJ, Court WS, Stegmann B, Heimbach RD, Sheffield PT.

Otolaryngol Head Neck Surg. 1997 Jun;116(6):703-704. doi: 10.1016/S0194-5998(97)70259-6. No abstract available.

PMID:
29389289
29.

Hyperbaric oxygen therapy.

Feldmeier JJ, Court WS, Davolt DA, Stegmann B, Heimbach RD, Sheffield PT.

Otolaryngol Head Neck Surg. 1997 Jun;116(6 Pt 1):703-4. No abstract available.

PMID:
9215393
30.

The formulary of a West Yorkshire pharmacy 1885-1927.

Court WE.

Pharm Hist (Lond). 1997 Mar;27(1):2-9. No abstract available.

PMID:
11618848
31.

A method to avoid misadministrations in high dose rate brachytherapy.

Alecu R, Feldmeier JJ, Court WS, Alecu M, Orton CG.

Med Phys. 1997 Feb;24(2):259-61. No abstract available.

PMID:
9048366
32.

Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis.

Feldmeier JJ, Heimbach RD, Davolt DA, Court WS, Stegmann BJ, Sheffield PJ.

Undersea Hyperb Med. 1996 Dec;23(4):205-13.

PMID:
8989850
33.

Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).

Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD.

Cancer Res. 1996 Jun 15;56(12):2815-22.

34.

Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio.

Forman JD, Duclos M, Sharma R, Chuba P, Hart K, Yudelev M, Devi S, Court W, Shamsa F, Littrup P, Grignon D, Porter A, Maughan R.

Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):259-66.

PMID:
8635931
35.

Hyperbaric oxygen as an adjunctive treatment for delayed radiation injury of the chest wall: a retrospective review of twenty-three cases.

Feldmeier JJ, Heimbach RD, Davolt DA, Court WS, Stegmann BJ, Sheffield PJ.

Undersea Hyperb Med. 1995 Dec;22(4):383-93.

PMID:
8574126
36.
37.

Alternating conformal neutron and photon irradiation for locally advanced adenocarcinoma of the prostate.

Forman JD, Warmelink C, Devi S, Court W, Sharma R, Yudelev M, Porter AT, Maughan R.

Am J Clin Oncol. 1995 Jun;18(3):231-8.

PMID:
7747712
38.

George Edward Trease (1902-1986) - a man of his time.

Court WE.

Pharm Hist (Lond). 1994 Dec;24(4):9-12. No abstract available.

PMID:
11613484
39.

Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.

Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ.

Cancer Res. 1994 Oct 1;54(19):5171-7.

40.

Preclinical models for the evaluation of targeted therapies of metastatic disease.

Eccles SA, Box G, Court W, Sandle J, Dean CJ.

Cell Biophys. 1994;24-25:279-91. Review.

PMID:
7736534
41.

Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy.

Eccles SA, Modjtahedi H, Box G, Court W, Sandle J, Dean CJ.

Invasion Metastasis. 1994-1995;14(1-6):337-48. Review.

PMID:
7657527
42.

Monoclonal antibodies for the treatment of metastases. Evaluation of strategies using a syngeneic rat model.

Eccles SA, Box G, Court W, Collins MK, Dean CJ.

Cell Biophys. 1993 Jan-Jun;22(1-3):165-87.

PMID:
7889538
43.

John Gerard and his herbal.

Court WE.

Pharm Hist (Lond). 1992 Aug;22(3):2-6. No abstract available.

PMID:
11623048
44.

General practice pharmacy in the 1840s. (Part two).

Court WE.

Pharm Hist (Lond). 1991 Sep;21(3):5-8. No abstract available.

PMID:
11612586
45.

General practice pharmacy in the 1840's.

Court WE.

Pharm Hist (Lond). 1991 Jun;21(2):2-4. No abstract available.

PMID:
11622884
46.

p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.

Stürzbecher HW, Maimets T, Chumakov P, Brain R, Addison C, Simanis V, Rudge K, Philp R, Grimaldi M, Court W, et al.

Oncogene. 1990 Jun;5(6):795-81.

PMID:
2141683
47.

Dental remedies--a pharmaceutical historical account.

Court WE.

Dent Hist. 1990 May;(18):3-18. No abstract available.

PMID:
2289376
48.

Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets.

Saleh M, Court W, Huster W, Shaw D, LoBuglio A.

Br J Haematol. 1988 Jan;68(1):47-51.

PMID:
3125855
49.

18th century drugs for the Royal Navy.

Court WE.

Pharm Hist (Lond). 1987 Sep;17(3):2-6. No abstract available.

PMID:
11612176
50.

The green pharmacists.

Court WE.

Pharm Hist (Lond). 1987;17(2):3-6. No abstract available.

PMID:
11612091

Supplemental Content

Support Center